Cassava Investors Get Class Certified In Alzheimer's Drug Suit
Investors accusing Cassava Sciences Inc. of inflating its stock price with manipulated research data of its Alzheimer's drug can proceed with their claims as a class, with the court finding the...To view the full article, register now.
Already a subscriber? Click here to view full article